EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effective treatment of advanced Oropouche virus, Rift Valley fever virus, and Dabie bandavirus infections with 4'-fluorouridine

Jonna B Westover iD, Kie Hoon Jung, Inioska Rojas, Kevin W Bailey, Julio Landinez-Aponte, Gregory R Blumeling, Shuli Mao, Alexander A Kolykhalov, Michael G Natchus, George R Painter, Brian B Gowen iD

mBio · 2025

DOI: 10.1128/mbio.01467-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Jonna B Westover und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Animal, Dairy and Veterinary Sciences, Institute for Antiviral Research, Utah State Universitys, Logan, Utah, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Bunyaviridae Infections, Orthobunyavirus. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oropouche virus (OROV), Rift Valley fever virus (RVFV), and Dabie bandavirus (DBV) are significant re-emerging and emerging human pathogens with major public health implications. Notably, the ongoing OROV disease epidemic spanning South America, Central America, and the Caribbean now exceeds 11,000 cases, including several fatalities and reports of neurological disease and congenital abnormalities associated with infection. Rift Valley fever outbreaks continue to plague sub-Saharan Africa, and DBV, the etiologic agent of severe fever with thrombocytopenia syndrome (SFTS), is expanding its reach throughout several Asian countries. No vaccines or approved therapies are available to prevent or treat these viral infections. Here, we report on the antiviral activity and protective efficacy of the ribonucleoside analog, 4′-fluorouridine (4′-FlU), against OROV, RVFV, and DBV in cell culture and murine models of infection and disease. In cell culture, the potency of 4′-FlU was in the low nanomolar (OROV) to low micromolar (RVFV and DBV) range. In vivo, prophylactic oral dosing of the compound was fully protective against all three viruses in their respective mouse infection models. Importantly, post-exposure and therapeutic interventions of advanced infections in mice also responded remarkably well to treatments. Our findings extend the broad-spectrum antiviral capacity of 4′-FlU and support the compound’s further development for treating severe bunyaviral infections. IMPORTANCE Re-emerging and emerging viral diseases, for which no approved vaccines or therapeutics exist, pose a significant public health threat in affected areas of the world. Antiviral drugs that are broadly active against multiple pathogenic viruses are much needed. Our findings demonstrating robust protection conferred by treatment with 4′-fluorouridine (4′-FlU) in viral infection models for Oropouche fever, Rift Valley fever, and severe fever with thrombocytopenia syndrome support the continuing development of this promising broad-spectrum antiviral drug candidate for the treatment of these notable viral diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsBunyaviridae InfectionsOrthobunyavirusAnimalsMiceDisease Models, AnimalRift Valley fever virusHumansFemaleCell LineTreatment Outcome

Stichwörter der Autor:innen

antiviral agentsbunyavirushuman pathogenpublic healthrodent model

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Animal, Dairy and Veterinary Sciences, Institute for Antiviral Research, Utah State Universitys, Logan, Utah, USA.
  • Emory Institute for Drug Development, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Jonna B Westover, Brian B Gowen

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Westover, J. B., Jung, K. H., Rojas, I., Bailey, K. W., Landinez-Aponte, J., Blumeling, G. R., Mao, S., Kolykhalov, A. A., Natchus, M. G., Painter, G. R., & Gowen, B. B. (2025). Effective treatment of advanced Oropouche virus, Rift Valley fever virus, and Dabie bandavirus infections with 4'-fluorouridine. mBio. https://doi.org/10.1128/mbio.01467-25

Vancouver

Westover JB, Jung KH, Rojas I, Bailey KW, Landinez-Aponte J, Blumeling GR, et al. Effective treatment of advanced Oropouche virus, Rift Valley fever virus, and Dabie bandavirus infections with 4'-fluorouridine. mBio. 2025. doi:10.1128/mbio.01467-25

BibTeX
@article{Westover2025,
  author = {Westover, Jonna B and Jung, Kie Hoon and Rojas, Inioska and Bailey, Kevin W and Landinez-Aponte, Julio and Blumeling, Gregory R and Mao, Shuli and Kolykhalov, Alexander A and Natchus, Michael G and Painter, George R and Gowen, Brian B},
  title = {Effective treatment of advanced Oropouche virus, Rift Valley fever virus, and Dabie bandavirus infections with 4'-fluorouridine},
  journal = {mBio},
  year = {2025},
  doi = {10.1128/mbio.01467-25}
}
Kostenlos starten →